This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
DUSA Pharmaceuticals Inc.
DUSA Pharmaceuticals Inc., a prominent player in the dermatology sector, is headquartered in the United States. Founded in 1991, the company has established itself as a leader in developing innovative therapies for skin conditions, particularly in the treatment of actinic keratosis and acne. DUSA's flagship product, Levulan® Kerastick®, is renowned for its unique photodynamic therapy approach, setting it apart in the competitive dermatological landscape. With a strong focus on research and development, DUSA Pharmaceuticals has achieved significant milestones, including expanding its product portfolio and enhancing patient access to effective treatments. The company’s commitment to quality and innovation has solidified its market position, making it a trusted name among healthcare professionals and patients alike.
DitchCarbon Score
How does DUSA Pharmaceuticals Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
DUSA Pharmaceuticals Inc.'s score of 67 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
DUSA Pharmaceuticals Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Sun Pharmaceutical Industries Limited, which may influence its climate commitments and reporting practices. As of now, DUSA Pharmaceuticals has not established any documented reduction targets or climate pledges. The absence of specific initiatives or targets suggests that the company may be in the early stages of developing its sustainability strategy. Given its affiliation with Sun Pharmaceutical Industries Limited, it is important to note that any climate-related initiatives or performance metrics may be derived from the parent company's practices. However, specific data or commitments from Sun Pharmaceutical Industries Limited have not been detailed in this context. In summary, while DUSA Pharmaceuticals Inc. does not currently provide emissions data or specific climate commitments, its relationship with Sun Pharmaceutical Industries Limited may play a role in shaping its future sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 77,616,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 377,728,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
DUSA Pharmaceuticals Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
